QuadMedicine

QuadMedicine EBIT Margin

The EBIT Margin (Operating Margin) of QuadMedicine (464490.KQ) as of Oct 30, 2026 is -47.82 %. In the previous year, EBIT Margin (Operating Margin) was -940.90 % — a change of -94.92% (higher).

EBIT Margin

-47.82 %

YoY

-94.92%

Last updated:

EBIT Margin (Operating Margin) of QuadMedicine is 2024 -47.82 % . EBIT Margin (Operating Margin) of QuadMedicine was 2023 -940.90 % . It decreases by -94.92% higher compared to the previous year.

For QuadMedicine, the operating (EBIT) margin of -47.8% is up versus -940.9% a few years ago.

The QuadMedicine EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2023
-940.90 KRW
Jan 1, 2024
-47.82 KRW
The QuadMedicine EBIT Margin history
YEAREBIT MarginYoY
-47.82 %-94.92%
-940.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

QuadMedicine Stock analysis

What does QuadMedicine do? QuadMedicine Inc operates through two segments: the Pharmaceutical segment, which develops synthetic drugs and vaccine products via the CDMO model, and the Other segment, which provides research services. The company generates revenue by offering contract development and manufacturing services for pharmaceutical products and research services to clients in the pharmaceutical industry. Clients include pharmaceutical companies seeking to outsource drug development and manufacturing, as well as organizations requiring specialized research support. The Pharmaceutical segment focuses on microneedle-based drug delivery systems, leveraging the company's R&D capabilities to create innovative solutions for drug administration. The Other segment supports clients with research services, likely targeting institutions and firms needing external expertise in pharmaceutical research. Revenue streams are directly tied to these service offerings, with no mention of product sales or other revenue sources beyond the described segments. QuadMedicine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about QuadMedicine stock

EBIT Margin (Operating Margin) of QuadMedicine is -47.82 % in 2024.

EBIT Margin (Operating Margin) of QuadMedicine changed from -940.90 % to -47.82 %, representing a -94.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) QuadMedicine since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s QuadMedicine with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — QuadMedicine

All Key Metrics — QuadMedicine